CD274 and neoplasm: In the Treated Cohort (#2), 18 patients whose tumours showed ≥50% PD-L1 expression were treated with pembrolizumab in first-line; 19 and 3 patients whose tumours had 1–49% PD-L1 expression were treated with pembrolizumab and nivolumab, respectively, in second-line after progression on chemotherapy.